Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

64.07USD
26 Sep 2016
Change (% chg)

-- (--)
Prev Close
$64.07
Open
--
Day's High
--
Day's Low
--
Volume
102
Avg. Vol
7,715,813
52-wk High
$68.12
52-wk Low
$45.45

Select another date:

Tue, Sep 20 2016

BRIEF-Karolinska Development: collaboration with AbbVie for Parkinson's Disease Research

* Its portfolio company BioArctic enters into collaboration with AbbVie for Parkinson's Disease Research

BRIEF-Abbvie sets quarterly cash dividend of $0.57per share

* Sets quarterly cash dividend of $0.57per share Source text for Eikon: Further company coverage:

Elliott Associates sues AbbVie over failed bid for Shire

Aug 5 AbbVie Inc said hedge fund Elliott Associates LP has sued the pharmaceuticals company alleging that it had made misrepresentations and omissions related to a failed attempt to buy Dublin-based Shire Plc .

Drugmaker AbbVie bumps up profit forecast on strong Humira sales

AbbVie Inc posted higher-than-expected quarterly profit and revenue, driven by demand for its flagship drug Humira, and raised its earnings forecast for the year.

UPDATE 2-Drugmaker AbbVie bumps up profit forecast on strong Humira sales

July 29 AbbVie Inc posted higher-than-expected quarterly profit and revenue, driven by demand for its flagship drug Humira, and raised its earnings forecast for the year.

AbbVie revenue jumps 17.8 pct on higher demand for drug Humira

July 29 AbbVie Inc's quarterly net revenue jumped 17.8 percent, driven by demand for its top-selling treatment, Humira.

BRIEF-AbbVie initiates late stage study of venetoclax in patients with relapsed or refractory multiple myeloma

* Venetoclax is being developed by abbvie and genentech, a member of roche group

BRIEF-Abbvie receives U.S. FDA approval of once-daily VIEKIRA XR

* Abbvie receives U.S. FDA approval of once-daily VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of genotype 1 chronic Hepatitis C

Samsung Bioepis seeks Europe approval for its Humira copy

SEOUL Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.

UPDATE 1-Samsung Bioepis seeks Europe approval for its Humira copy

* European Medicines Agency reviewing Samsung Bioepis' application

Select another date: